About us
We are Pioneering Molecular Glue Therapies for Hard-to-Treat Diseases
TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel molecular glue therapeutics to treat diseases that are difficult to address with any other modality.
Our approach is centered on advancing promising discoveries based on induced proximity into new treatments. TRIANA’s initial programs are aimed at targeted protein degradation, with a particular focus on developing innovative new medicines for people with cancer.
Our technology identifies small molecules that promote the interaction between two proteins which alters the fate or function of the disease target protein. One such application aims to activate the innate protein degradation machinery to destroy the disease target. These innovative “molecular glues” allow us to treat diseases in entirely new ways, by pursuing highly relevant disease targets that have long been inadequately addressed.
Our target-first and rational approach to molecular glue discovery enables us to consider a wide range of therapeutic applications for our products. Our drug discovery efforts are advanced with emphasis on known disease-causing protein targets.
The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring substantial therapeutic benefit to patients.
Our Team
Leadership Team
Patrick Trojer, PhD
President & Chief Executive Officer
Patrick Trojer, PhD
President & Chief Executive Officer
Dr. Trojer joined TRIANA Biomedicines in November of 2021 as CEO and Board member after a successful career at Constellation Pharmaceuticals, where he served as the company’s CSO. Dr. Trojer co-founded Constellation in 2008 and, as a member of the company’s executive team, he materially contributed to several successful financing rounds and deals, including a $100M crossover round, a $65M IPO, and the ultimate acquisition of Constellation in 2021 for $1.7B. Under his leadership, Constellation built a robust discovery platform, established a portfolio of competitive clinical candidates, and drove the maturation of the company’s development efforts, leading to one PhIII and two PhII assets and three additional clinical candidates. Dr. Trojer brings 20+ years of experience in transcription and chromatin regulation and 15+ years of drug discovery and oncology experience to TRIANA. He completed his post-doctoral fellowship at NYU Medical School in the laboratory of Dr. Danny Reinberg and received his Ph.D. in Biochemistry and Molecular Biology from the Leopold-Franzens University of Innsbruck, Austria.
Caroline Germa, MD
Chief Medical Officer
Caroline Germa, MD
Chief Medical Officer
Dr. Germa joined TRIANA Biomedicines in May of 2025 to lead the clinical development of the company’s therapeutic products. She is an accomplished medical oncologist and clinical development leader with approximately 25 years of pharmaceutical industry experience in smaller biotech and large pharmaceutical companies, from first-in-human to registrational clinical studies. She led the initial Kisqali® program and registration, and actively contributed to the development of multiple other small molecules and biologics, of which several received FDA approval. Prior to joining TRIANA, she was the CMO at Ikena Oncology, where she led the clinical efforts in developing the company’s pipeline. Dr. Germa also served as the CMO at Transcenta Therapeutics, where she played a pivotal role in shaping and successfully executing on the strategic goals for the company’s oncology and non-oncology portfolio in China, the US, and the rest of the world. In addition, Dr. Germa held senior clinical leadership positions at global pharmaceutical companies such as AstraZeneca, Bristol Myers Squibb, and Novartis. Dr. Germa earned her Medical Doctor degree and board certification in Medical Oncology at the University of Lille, France.
Vito Palombella, PhD
Chief Scientific Officer
Vito Palombella, PhD
Chief Scientific Officer
Dr. Palombella joined TRIANA Biomedicines in September of 2023. He brings to TRIANA over 30 years of scientific leadership and experience advancing first-in-class therapeutic programs, as well as a successful track record of building drug discovery and development organizations. Prior to joining TRIANA, he was the Chief Scientific Officer (CSO) at Surface Oncology, where he led the non-clinical research and development organization. Prior to that, Dr. Palombella was EVP and CSO at Infinity Pharmaceuticals, where he was responsible for drug discovery and preclinical development. He held roles of increasing scientific responsibility at Syntonix Pharmaceuticals, Millennium Pharmaceuticals, LeukoSite Inc., and ProScript. Dr. Palombella was involved in the discovery and development of bortezomib and duvelisib, both for cancer therapy. Dr. Palombella holds a PhD in Viral Oncology and Immunology from the New York University Medical Center and completed his postdoctoral studies at Harvard University.
Mohan Bala, PhD
Chief Operating Officer
Mohan Bala, PhD
Chief Operating Officer
Dr. Bala joined TRIANA Biomedicines in May 2026, bringing more than 30 years of experience in program leadership, program development, market access, product strategy, and business development. His expertise spans the full development continuum, from early to late-stage programs, across both small biotech and large pharmaceutical organizations. He has successfully launched seven oncology products globally. Prior to joining TRIANA, he served as Chief Development Officer at Mersana Therapeutics, where he played a key role in business development efforts that culminated in the company’s acquisition by Day One Biopharmaceuticals. Before that, he was Chief Operating Officer at Constellation Pharmaceuticals, where he led multiple development functions, while also contributing significantly to the business activities that led to the company’s acquisition by MorphoSys. Earlier in his career, Dr. Bala held roles of increasing responsibility at TESARO, Sanofi, GlaxoSmithKline, Centocor, and Research Triangle Institute. He holds a Ph.D. in Management Science from the University of Chicago.
Brenda Sousa
Acting Head of Human Resources
Brenda Sousa
Acting Head of Human Resources
Ms. Sousa joined the TRIANA Biomedicines’ team in November 2021 as a people and culture advisor. She brings to TRIANA decades of people, culture and human resources experience in early stage biotechnology organizations. Prior to joining TRIANA, she was the Chief Human Resources Officer at Constellation Pharmaceuticals, where she led the organization through multiple stages of growth from an early research focus to a publicly traded, pre-commercial business and subsequent successful acquisition. Previously, Ms. Sousa was the Vice President of Human Resources and Operations at EPIX Pharmaceuticals. Ms. Sousa held positions of increasing responsibility at RKS Health Ventures concluding with an acquisition by Partners Healthcare. Ms. Sousa received her BS from the University of Massachusetts.
Louis Plamondon, PhD
Executive Vice President, Pharmaceutical Development
Louis Plamondon, PhD
Executive Vice President, Pharmaceutical Development
Dr. Plamondon joined TRIANA Biomedicines in October 2024 to lead the manufacturing and drug development of the company’s therapeutic products. He brings to TRIANA over three decades of chemistry, manufacturing, and drug development experience in both biotech and large pharmaceutical industry settings, and is a recognized leader in the discovery, development, and commercialization of small molecule therapeutics. Prior to joining TRIANA, he was the Executive Vice President and Head of CMC at LifeMine Therapeutics. Previously, at Constellation Pharmaceuticals, Dr. Plamondon was the Senior Vice President of CMC and led the manufacturing and development of all small molecule therapeutic products for the company from Phase I to NDA preparation activities. Dr. Plamondon held positions of increasing responsibility at Vertex Pharmaceuticals, Karyopharm Therapeutics, Tetraphase Pharmaceuticals, Millennium Pharmaceuticals, and Bio-Mega/Boehringer Ingelheim, and he is an inventor on multiple patents. Dr. Plamondon received his PhD from the University of Montreal and completed his postdoctoral research in the laboratory of Professor Stuart Schreiber at Harvard University.
Kathleen Seyb, PhD
Senior Vice President, Biology & Translational Sciences
Kathleen Seyb, PhD
Senior Vice President, Biology & Translational Sciences
Dr. Seyb joined TRIANA Biomedicines in September of 2021 to build and lead the biology and translational sciences team. Previously, she served as Vice President of Research at Ohana Biosciences, where she focused on developing novel treatments to improve reproductive health. Prior to Ohana, Dr. Seyb held positions of increasing responsibility at Ra Pharmaceuticals, where she was the biology lead for programs spanning discovery through Phase 2 clinical development and served as program lead for the company’s collaboration with Merck that yielded an orally bioavailable tricyclic peptide inhibitor of PCSK9. Dr. Seyb received her Ph.D. in Pharmacology and Toxicology from the University of Kansas.
Alex Constan, PhD
Senior Vice President, Nonclinical Development
Alex Constan, PhD
Senior Vice President, Nonclinical Development
Dr. Constan joined TRIANA Biomedicines in March 2025. He has over 25 years of experience in nonclinical safety assessment, drug development strategy, and regulatory submissions. He has led toxicology, DMPK, and clinical pharmacology functions in various therapeutic areas and drug modalities. Most recently, he was an independent consultant and guided early nonclinical programs to IND submission for small biotech companies. Previously, he was responsible for the safety evaluation of small molecule and gene therapy programs and oversaw oncology programs from early discovery through late-stage development at Ikena Oncology, Decibel Therapeutics, Infinity Pharmaceuticals, Pfizer, and Rhône-Poulenc Rorer Pharmaceuticals. Dr. Constan earned his Ph.D. in Environmental Toxicology at Colorado State University and trained as a post-doctoral fellow at the Chemical Industry Institute of Toxicology (CIIT) in Research Triangle Park, NC.
Andrew Marsh
Senior Vice President, Development Operations
Andrew Marsh
Senior Vice President, Development Operations
Mr. Marsh joined TRIANA Biomedicines in September 2025 to lead and build the clinical development operations of the company’s therapeutic products. He is an accomplished drug development professional bringing to TRIANA over two decades of development operations experience in both biotech and large pharmaceutical industry settings. Prior to joining TRIANA, he was the Vice President of Clinical Development Operations at Mariana Oncology, a Novartis Company, Vigil Neurosciences, and Synlogic. Mr. Marsh has proven experience in building out clinical development operations functions from the ground up and leading nimble clinical teams through first-in-human trials, proof of concept, and beyond. He has contributed to the development of three approved products, most recently ZILBRYSQ®, and brings a patient-centric focus to clinical development with an emphasis on representing the patients’ voice from study design concept through trial execution. Mr. Marsh has held positions of increasing responsibility at Ra Pharmaceuticals, Onkaido, a Moderna Company, Tetraphase Pharmaceuticals, and Ziopharm Oncology. Mr. Marsh received his BSc in Biomedical Engineering from Boston University.
Fatou Ndiaye
Senior Vice President, Finance
Fatou Ndiaye
Senior Vice President, Finance
Ms. Ndiaye joined TRIANA Biomedicines in August 2022 to build and lead a fully integrated finance organization. She brings to TRIANA over 18 years of financial expertise in the life science industry, driving operational and strategic initiatives across global pharmaceutical organizations as well as early- to mid-stage biotech companies. Prior to joining TRIANA, she worked as a senior consultant with Danforth Advisors, leading and optimizing their FP&A practice. Previously, Ms. Ndiaye was Sr. Director of Finance at Sunovion Pharmaceuticals, where she led the R&D Clinical Finance team through change management, with a focus on developing and optimizing the planning, analysis, and reporting for both Sunovion US and global clinical development business units. As the Sr. Director Finance and Operations at IFM Therapeutics, she built the company’s FP&A capability. Ms. Ndiaye held positions of increasing responsibility at Aileron Therapeutics, Genocea Biosciences, and Takeda / Millennium Pharmaceuticals. Ms. Ndiaye received her Masters in Finance from Boston College.
Daniel La, PhD
Vice President, Medicinal Chemistry
Daniel La, PhD
Vice President, Medicinal Chemistry
Dr. La joined TRIANA Biomedicines in November 2021. He has more than twenty years of drug discovery experience. Prior to joining the company, he was Head of Medicinal Chemistry and Structural Biology at FogPharma (currently Parabilis Medicines), where he was the scientific program lead for the company’s flagship beta-catenin program. Previously, he was at Sage Therapeutics and Amgen Inc., where he held roles of increasing responsibility on program teams that ranged from early discovery to IND filing. He has over 70 patents and publication. Dr. La holds a Ph.D. in Chemistry from Boston College and a post-doctoral research fellowship from Harvard University.
Tim Wigle, PhD
Vice President, Lead Discovery
Tim Wigle, PhD
Vice President, Lead Discovery
Dr. Wigle joined TRIANA Biomedicines in March 2022 to build the Lead Discovery Team. He has over 15 years of drug discovery experience. Prior to joining the company, he was Senior Director of Molecular Discovery at Ribon Therapeutics, where he helped deliver three assets into clinical trials. Previously, he was Associate Director of Biochemistry and Biophysics at Warp Drive Bio, where he oversaw a team of scientists responsible for identifying small molecules that induce ternary complexes. He held roles of increasing responsibility and scientific scope at Epizyme. Dr. Wigle holds a Ph.D. in Pharmaceutical Sciences from The University of North Carolina at Chapel Hill and completed a post-doctoral research fellowship at the Center for Integrative Chemical Biology & Drug Discovery at The University of North Carolina at Chapel Hill.
Connie Freund
Vice President, Regulatory Affairs
Connie Freund
Vice President, Regulatory Affairs
Ms. Freund joined TRIANA Biomedicines in July 2026 to lead the regulatory strategy for the Company’s molecular glue therapeutic portfolio. She brings more than 25 years of pharmaceutical industry experience, spanning global regulatory strategy and product development, from early-stage IND submissions through late-stage NDA and MAA filings, with particular expertise in oncology. Prior to joining TRIANA, she was the Vice President of Global Regulatory Affairs at Stemline Therapeutics, where she led the development and execution of global regulatory strategies across the company’s portfolio and with various collaboration partners to support efficient and competitive global development programs. Previously, she held positions of increasing regulatory responsibility at Gilead Sciences, GlaxoSmithKline, Novartis Pharmaceuticals, International AIDS Vaccine Initiative, and PTC Therapeutics. Ms. Freund received her MS in Regulatory Affairs from Northeastern University.
Board Members
Jigar Raythatha
Chair of the Board, Independent Board Director
Shelley Chu, MD, PhD
Lightspeed Venture Partners
David Grayzel, MD
Atlas Venture
Andrew Hedin
Bessemer Venture Partners
Lorence Kim, MD
Ascenta Capital
Christopher O’Donnell, PhD
Pfizer Ventures
Josh Resnick, MD
RA Capital Management
Patrick Trojer, PhD
President & CEO, TRIANA Biomedicines
Scientific Advisory Board
Robert Abraham, PhD
Chair of the SAB
Robert Copeland, PhD
Scientific Advisor
Brian Jones, PhD
Scientific Advisor
Maria Koehler
Scientific Advisor
Adrian Senderowicz, MD
Scientific Advisor
Supported by World-
Class Investors
Ascenta Capital
Atlas Venture
Bessemer Venture Partners
Citadel
Finchley Healthcare Ventures
Invus
Lightspeed
Pfizer Ventures
RA Capital
Regeneron Ventures
YK Bioventures